Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.
Vingiani A, Agnelli L, Duca M, Lorenzini D, Damian S, Proto C, Niger M, Nichetti F, Tamborini E, Perrone F, Piccolo A, Manoukian S, Azzollini J, Brambilla M, Colombo E, Lopez S, Vernieri C, Marra F, Conca E, Busico A, Capone I, Bozzi F, Angelini M, Devecchi A, Salvatori R, De Micheli V, Baggi A, Pasini S, Jommi C, Ladisa V, Apolone G, De Braud F, Pruneri G. Vingiani A, et al. Among authors: pruneri g. JCO Precis Oncol. 2023 Jul;7:e2300067. doi: 10.1200/PO.23.00067. JCO Precis Oncol. 2023. PMID: 37487147 Free PMC article.
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples.
Capone I, Bozzi F, Dagrada GP, Verderio P, Conca E, Busico A, Testi MA, Monti V, Duca M, Proto C, Damian S, Piccolo A, Perrone F, Tamborini E, Devecchi A, Collini P, Lorenzini D, Vingiani A, Agnelli L, Pruneri G. Capone I, et al. Among authors: pruneri g. Explor Target Antitumor Ther. 2022;3(5):582-597. doi: 10.37349/etat.2022.00102. Epub 2022 Oct 27. Explor Target Antitumor Ther. 2022. PMID: 36338518 Free PMC article.
Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.
Centonze G, Maisonneuve P, Prinzi N, Pusceddu S, Albarello L, Pisa E, Barberis M, Vanoli A, Spaggiari P, Bossi P, Cattaneo L, Sabella G, Solcia E, La Rosa S, Grillo F, Tagliabue G, Scarpa A, Papotti M, Volante M, Mangogna A, Del Gobbo A, Ferrero S, Rolli L, Roca E, Bercich L, Benvenuti M, Messerini L, Inzani F, Pruneri G, Busico A, Perrone F, Tamborini E, Pellegrinelli A, Kankava K, Berruti A, Pastorino U, Fazio N, Sessa F, Capella C, Rindi G, Milione M. Centonze G, et al. Among authors: pruneri g. Neuroendocrinology. 2023;113(4):457-469. doi: 10.1159/000528186. Epub 2022 Nov 23. Neuroendocrinology. 2023. PMID: 36417840 Free article.
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers.
Lo Russo G, Sgambelluri F, Prelaj A, Galli F, Manglaviti S, Bottiglieri A, Di Mauro RM, Ferrara R, Galli G, Signorelli D, De Toma A, Occhipinti M, Brambilla M, Rulli E, Triulzi T, Torelli T, Agnelli L, Brich S, Martinetti A, Dumitrascu AD, Torri V, Pruneri G, Fabbri A, de Braud F, Anichini A, Proto C, Ganzinelli M, Mortarini R, Garassino MC. Lo Russo G, et al. Among authors: pruneri g. ESMO Open. 2022 Dec;7(6):100645. doi: 10.1016/j.esmoop.2022.100645. Epub 2022 Nov 28. ESMO Open. 2022. PMID: 36455507 Free PMC article. Clinical Trial.
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
Ferrando L, Vingiani A, Garuti A, Vernieri C, Belfiore A, Agnelli L, Dagrada G, Ivanoiu D, Bonizzi G, Munzone E, Lippolis L, Dameri M, Ravera F, Colleoni M, Viale G, Magnani L, Ballestrero A, Zoppoli G, Pruneri G. Ferrando L, et al. Among authors: pruneri g. PLoS Genet. 2023 Jan 3;19(1):e1010563. doi: 10.1371/journal.pgen.1010563. eCollection 2023 Jan. PLoS Genet. 2023. PMID: 36595552 Free PMC article.
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.
Lobefaro R, Mariani L, Peverelli G, Ligorio F, Fucà G, Rametta A, Zattarin E, Leporati R, Presti D, Cantarelli B, Depretto C, Vingiani A, Manoukian S, Scaperrotta G, Bianchi GV, Capri G, Pruneri G, de Braud F, Vernieri C. Lobefaro R, et al. Among authors: pruneri g. Clin Breast Cancer. 2023 Apr;23(3):e151-e162. doi: 10.1016/j.clbc.2022.12.008. Epub 2022 Dec 17. Clin Breast Cancer. 2023. PMID: 36599769 Free article.
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer.
Castagnoli L, Corso S, Franceschini A, Raimondi A, Bellomo SE, Dugo M, Morano F, Prisciandaro M, Brich S, Belfiore A, Vingiani A, Di Bartolomeo M, Pruneri G, Tagliabue E, Giordano S, Pietrantonio F, Pupa SM. Castagnoli L, et al. Among authors: pruneri g. Cell Oncol (Dordr). 2023 Jun;46(3):661-676. doi: 10.1007/s13402-023-00769-x. Epub 2023 Feb 8. Cell Oncol (Dordr). 2023. PMID: 36753044 Free PMC article.
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.
Di Cosimo S, Ciniselli CM, Pizzamiglio S, Cappelletti V, Silvestri M, El-Abed S, Izquierdo M, Bajji M, Nuciforo P, Huober J, Cameron D, Chia S, Gomez HL, Iorio MV, Vingiani A, Pruneri G, Verderio P. Di Cosimo S, et al. Among authors: pruneri g. Front Oncol. 2023 Jan 31;12:1028825. doi: 10.3389/fonc.2022.1028825. eCollection 2022. Front Oncol. 2023. PMID: 36798690 Free PMC article.
407 results